Outset Medical Gets FDA's Clearance For Its Tablo Platform

Outset Medical, Inc. (Nasdaq: OM) has received 510(k) clearance from the U.S. FDA for its next-generation Tablo platform, which aims to improve clinical outcomes in dialysis while reducing costs and complexity. This makes Tablo the first hemodialysis system to comply with the FDA's latest cybersecurity guidance. The platform features enhancements in hardware, operating system, and software to improve reliability and user experience.